



New dibenzocyclooctadiene lignans from the *Kadsura ananosma*

Jian-Hong Yang^{a,d}, Hai-Yan Zhang^b, Xue Du^a, Wei Wang^b, Wei-Lie Xiao^a, Jin Wen^c, Jian-Xin Pu^{a,*}, Xi-Can Tang^b, Han-Dong Sun^{a,*}

^a State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650204, Yunnan, People's Republic of China

^b State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, People's Republic of China

^c Yunnan Academy of Forest Sciences, Institute of Tropical Forestry, Kunming 650204, People's Republic of China

^d Graduate University of Chinese, Academy of Sciences, Beijing 100039, People's Republic of China

ARTICLE INFO

Article history:

Received 8 March 2011

Received in revised form 19 April 2011

Accepted 29 April 2011

Available online 6 May 2011

Keywords:

Kadsura ananosma

Dibenzocyclooctadiene lignans

Ananonins

Neuroprotective effect

ABSTRACT

Fourteen new dibenzocyclooctadiene lignans, ananonins A–N (**1–14**), together with five known compounds, were isolated from the seeds of *Kadsura ananosma*. The structures and absolute configurations of **1–14** were established using a combination of MS, NMR, and CD techniques. The biological activity of these compounds was evaluated, and ananonin M (**13**) showed moderate neuroprotective effects in an in vitro assay.

© 2011 Elsevier Ltd. All rights reserved.

1. Introduction

The genus of *Kadsura* belongs to the family Schisandraceae. Some species of this genus have been reported to contain dibenzocyclooctadiene lignans, lanostane and cycloartane triterpenoids.^{1–4} Previous pharmacological studies have indicated that the principle bioactive constituents of *Kadsura* medicinal plant were lignans, especially the dibenzocyclooctadiene type, some of which possessed antitumor,⁵ anti-HIV,^{6,7} and cytotoxic⁸ effects.

Kadsura ananosma Kerr is a liana indigenous to Yunnan Province, People's Republic of China.⁹ Previous work mainly focus on the investigation of the stems of this species and led to the isolation of triterpenoids, sesquiterpenoids, and lignans.^{10–16} For further comprehensive acquaint with the constituents of this plant and search for biologically active natural products, we reinvestigated the seeds of *K. ananosma*, and this paper reports on the isolation and structure elucidation of new dibenzocyclooctadiene lignans, ananonins A–N (**1–14**), and the known compounds tiegusanin I (**15**),¹⁷ pre-gomisin (**16**),¹⁸ kadangustin H (**17**),¹⁹ kadangustin I (**18**),¹⁹ and 10-hydroxyl-15-oxo- α -cadinol (**19**, Fig. 1).²⁰ The structures of these new compounds **1–14** were established by means of




Fig. 1. Compounds isolated from *K. ananosma*.

MS and extensive NMR spectra, and the absolute configurations of these new compounds were determined by CD and ROESY experiments. In this paper, the isolation, structure elucidation, and the anti-neurodegenerative activity are reported.

* Corresponding authors. Tel.: +86 871 5223251; fax: +86 871 5216343; e-mail addresses: pujianxin@mail.kib.ac.cn (J.-X. Pu), hdsun@mail.kib.ac.cn (H.-D. Sun).

2. Results and discussion

Ananonin A (**1**) was assigned a molecular formula of $C_{30}H_{32}O_9$, according to HRESIMS m/z 559.1930 $[M+Na]^+$ (calcd 559.1944), which requires 15° of unsaturation. The UV spectrum showed λ_{max} (CHCl₃) values at 214, 221, and 241 nm. The IR spectrum showed the presence of a hydroxy group (3444 cm^{-1}) and a conjugated ester (1733 cm^{-1}). The 1D NMR spectra exhibited 18 carbon atoms (including 12 aromatic ones, four methines, and two secondary methyls) for the dibenzocyclooctadiene skeleton,²¹ in addition to one benzoyloxy group (δ_C 165.4s, 130.1s, 129.6d, 127.9d, 132.8d, 127.9d, and 129.6d),¹⁷ one methylenedioxy group, and four methoxy groups. HMBC correlations of the methylenedioxy protons with C-12 and C-13, and of the four methoxy group signals with C-1, C-2, C-3, and C-14, showed that the methylenedioxy group is connected to C-12 and C-13, and the four methoxy groups are located at C-1, C-2, C-3, and C-14, respectively. The presence of the benzoyloxy group at C-6 was deduced from the HMBC correlation of H-6 (δ_H 5.98) with the ester carbonyl (δ_C 165.4, C-1'). According to the molecular formula, the benzylic oxymethine at C-9 should be substituted by a hydroxy group (Fig. 1).

The CD spectrum of **1** exhibited a positive Cotton effect at λ_{max} 225 nm and a negative value at λ_{max} 248 nm, indicating a *S*-biphenyl configuration.²¹ With the axial chirality defined, a ROESY experiment was used to establish the absolute configuration of the remaining stereocenters. The observed ROESY correlations of H-11 with H-8 and H-9, of H-4 with H-6 and H₃-17, and of H₃-17 with H₃-18 indicated that H-6, CH₃-17, and CH₃-18 are α -oriented, and that H-9 is β -oriented (Fig. 2). The proton coupling constants of H-6 (δ_H 5.98, $d, J=7.0$ Hz) and H-9 (δ_H 4.71, s) further confirmed the above deductions. These conclusions were consistent with **1** being a cyclooctadiene lignan with a twisted boat/chair conformation having C-7 (*R*), C-8 (*R*), and C-9 (*R*) absolute configurations. Thus, the structure of **1** was established as shown, and named anononin A.




Fig. 2. Key HMBC and ROESY correlations of **1**.

Comparison of the NMR data of **1** with those of compounds **2–6** disclosed that the main structural differences between these compounds concerned the substituent at C-9. Ananonin B (**2**) gave a molecular formula of $C_{32}H_{34}O_{10}$ by HRESIMS at m/z 601.2059 $[M+Na]^+$ (calcd 601.2049). The ¹³C NMR and DEPT data of **2** indicated the presence of an acetyl group (δ_C 170.1s, and 20.7q). The HMBC correlation of H-9 (δ_H 5.75) with the acetate carbonyl carbon (δ_C 170.1) led to the positioning of the acetyl group at C-9. The molecular formula of **3** was determined as $C_{33}H_{36}O_{10}$ by HRESIMS at m/z 615.2190 $[M+Na]^+$ (calcd 615.2206), and the NMR data of **3** also showed similarities with the analogous values for **1**. However, a signal for a propionyl group (δ_C 173.5s, 27.1t, and 8.6q) was evident at C-9 in **3**, which was confirmed by the HMBC correlations from H-9 (δ_H 5.76) to the ester carbonyl (δ_C 173.5, C-1'). Ananonins D (**4**), E (**5**), and F (**6**) showed molecular ions at m/z 629.2366, 629.2367, and 643.2504 in their HRESIMS, corresponding to the molecular formulas, $C_{34}H_{38}O_{10}$, $C_{34}H_{38}O_{10}$, and $C_{35}H_{40}O_{10}$, respectively. The major differences were in the replacement of

a hydroxy group at C-9 in **1** by a butyryl group (δ_C 172.8s, 35.8t, 17.9t, and 13.6q) in **4**, by an isobutyryl group (δ_C 176.5s, 33.7d, 18.1q, and 19.3q) in **5**, and by an isovaleryl group (δ_C 176.0s, 40.2d, 26.6t, 11.2q, and 15.2q) in **6**.¹⁷

The CD, UV, and IR data suggested that **2–6** are *S*-biphenyl-configured dibenzocyclooctadiene lignans. ROESY correlations obtained for **2–6** were shown from H-11 to H-8 and H-9, from H-4 to H-6 and H₃-17, and from H₃-17 to H₃-18 indicated that H-6, CH₃-17 and CH₃-18 are α -oriented, and that H-9 is β -oriented. Thus, the structures of anononins B–F (**2–6**) were established as shown.

Ananonin G (**7**) was assigned as $C_{33}H_{42}O_{10}$, as deduced from the HRESIMS (m/z 621.2660 $[M+Na]^+$) and in accordance with its NMR data. The UV, IR, CD, and NMR spectra of **7** suggested the presence of a *S*-biphenyl-configured dibenzocyclooctadiene lignan with almost identical data to **6**, except for the substituent at C-6. Analysis of the 1D NMR data showed an angeloyloxy group (δ_C 166.7s, 127.9s, 138.5d, 15.5q, and 19.9q) in **7** instead of a benzoyloxy group in **6**, which was deduced from an HMBC correlation of H-6 (δ_H 5.83) with ester carbonyl (δ_C 166.7, C-1'). The configuration of **7** was determined through ROESY correlations of H-11/H-8, H-9; H-4/H-6, H₃-17; and H₃-18/H₃-17, as well as the proton coupling constants of H-6 ($d, J=8.1$ Hz) and H-9 ($br\ s$), which were in agreement with a cyclooctadiene lignan with a twisted boat/chair conformation having C-6 (*R*), C-7 (*S*), C-8 (*R*), and C-9 (*R*) absolute configurations. Therefore, the structure of anononin G (**7**) was determined as shown.

The molecular formula of anononin H (**8**) was assigned as $C_{29}H_{34}O_{10}$, on the basis of the HRESIMS (m/z 565.2034 $[M+Na]^+$). The 1D NMR spectra exhibited 18 carbon atoms (including 12 aromatic ones, four methines, and two secondary methyls) for the dibenzocyclooctadiene skeleton, in addition to an angeloyloxy group (δ_C 166.7s, 127.4s, 139.0d, 15.6q, and 20.0q), a methylenedioxy group, three methoxy groups, and an acetyl group. The existence of the acetyl group and the angeloyloxy group at C-9 and C-6, respectively, was deduced from the HMBC correlations of H-6 (δ_H 5.75) with ester carbonyl (δ_C 166.7, C-1'), and of H-9 (δ_H 5.72) with acetate carbonyl (δ_C 169.9) (Fig. 3). Further analysis of the HMBC spectrum showed that the methylenedioxy group was located at C-12 and C-13, and the three methoxy groups were located at C-1, C-2, and C-3, respectively. According to the molecular formula, the quaternary carbon at C-14 should be substituted by a hydroxy group. The biphenyl group in **8** was determined to have a *S*-biphenyl configuration from its CD spectrum. The observed ROESY correlations of H-11 with H-8 and H-9, of H-4 with H-6 and H₃-17, and of H₃-17 with H₃-18 indicated that H-6, CH₃-17 and CH₃-18 are α -oriented, and that H-9 is β -oriented. Therefore, the structure of anononin H (**8**) was determined as shown.




Fig. 3. Key HMBC and ROESY correlations of **8**.

Ananonins I (**9**) and J (**10**) were assigned with the molecular formula, $C_{30}H_{36}O_{10}$ and $C_{32}H_{40}O_{10}$, as determined by HRESIMS (m/z 579.2212 $[M+Na]^+$, and 607.2504 $[M+Na]^+$, respectively). The main difference found between **8**, **9**, and **10** concerned the substituent

group located at C-9. Analysis of the NMR data showed a propionyl group at C-9 in **9**, and a isovaleryl group in **10**, instead of an acetyl group in **8**, which was deduced from an HMBC correlation of H-9 (δ_{H} 5.76) with ester carbonyl (δ_{C} 173.4, C-1'') in **9**, and of H-9 (δ_{H} 5.75) with ester carbonyl (δ_{C} 176.2, C-1'') in **10**. By comparison of CD, UV, and ROESY spectra with those of **8**, compounds **9** and **10** were also assigned S-biphenyl-configured dibenzocyclooctadiene lignans with twisted boat/chair conformation of the cyclooctadiene ring and quasi-axial CH₃-17 and quasi-equatorial CH₃-18.

Ananonins K (**11**) showed the molecular ion peak $[M+Na]^+$ at m/z 541.2059 (calcd 541.2049) in the HRESIMS, corresponding to the molecular formula C₂₇H₃₄O₁₀. The 1D NMR of **11** indicated the presence of 12 aromatic carbons, two aromatic protons, five methoxy, and two acetyl groups, implied that **11** is a dibenzocyclooctadiene lignan possessing a hydroxy group. HMBC correlations of H-11 with C-9, C-10, C-12, C-13, and C-15, and H-4 with C-2, C-3, C-5, C-6, and C-16, and ¹H–¹H COSY correlations of H-6/H-7/H-8/H-9, H-7/H₃-17, and H-8/H₃-18 (Fig. 3) confirmed the above conclusion. Further analysis of the HMBC spectrum showed five methoxy groups to be located at C-1, C-2, C-3, C-13, and C-14, respectively, indicated that a hydroxy group was located at C-12 according to the molecular formula. The two acetyl groups assigned to C-6 and C-9, according to the HMBC correlations of H-6 and H-9 with acetate carbonyl.

The CD curve of **11** showed a negative Cotton effect around 250 nm and a positive value around 210 nm, suggesting that **11** possesses a S-biphenyl configuration. ROESY correlations of H-11 with H-8 and H-9, and of H-4 with H-6 and H₃-17, suggested a cyclooctadiene lignan with a twisted boat/chair conformation of **11**, consistent with the absolute configurations C-6 (R), C-7 (S), C-8 (R), and C-9 (R). Therefore, the structure of ananonin K (**11**) was determined as shown.

Analysis of the 2D NMR data of ananonins L–N (**12**–**14**) and comparison of their 1D NMR data with those of **11** revealed that the main structure differences between these compounds were the substituent patterns at C-6 and C-9. The 1D NMR spectra of **12** indicated the characteristic signals for an angeloyloxy group (δ_{C} 166.7s, 127.7s, 138.8d, 15.6q, and 20.7q), which was determined to be located at C-6 by HMBC correlations of H-6 with C-1' (δ_{C} 166.7). Similarly, the 1D NMR spectra of **13** were very close to those of **11** except for the characteristic signals for a benzoyloxy group (δ_{C} 165.4s, 130.0s, 129.6d, 128.1d, 132.9d, 128.1d, and 129.6d) at C-6. HMBC correlations of H-6 with C-1' (δ_{C} 165.4) in **13** established the location of the benzoyloxy moiety at C-6. By contrast, the only difference between **13** and **14** was the substituent at C-9. There was a hydroxy group at C-9 in **13** while an acetyl group substituent in **14**, which was in accord with the observation of remarkable downfield shift of the signal of H-9 from δ_{H} 4.73 in **13** to δ_{H} 5.78 in **14**. By comparison of CD, UV, and ROESY spectra with those of **11**, compounds **12**–**14** were assigned as S-biphenyl-configured dibenzocyclooctadiene ring. Therefore, the structures of compounds **12**–**14** were determined as shown.

The neuroprotective effects of all dibenzocyclooctadiene lignans were evaluated according to a reported in vitro protocol²² using SH-SY5Y neuroblastoma cells, a widely used neuroblastoma cell line for study of neurodegenerative disease.^{23,24} As may be seen from Table 5, ananonin M (**13**) showed moderate neuroprotective effect against oxidative stress-induced neurotoxicity of these compounds tested. Due to limitations in the amounts available, compound **4** was not tested in the bioassay used.

3. Conclusion

In summary, this paper describes the isolation and structure elucidation of 14 new dibenzocyclooctadiene lignans, ananonins A–N (**1**–**14**), as well as five known compounds from the seeds of *K. ananosma*, while our previous researches exhibited that the remarkably varied triterpenoids are mainly constituents of the stems

of *K. ananosma*.^{15,16} Our present research expanded considerably the library for dibenzocyclooctadiene lignans and also illuminated the variety of the metabolites in different parts of *K. ananosma*. Particularly, ananonin M (**13**) showed moderate neuroprotective effect in an in vitro cell survival assay.

4. Experimental

4.1. General procedures

Optical rotations were measured with a Horiba SEPA-300 polarimeter. UV spectra were obtained using a Shimadzu UV-2401A spectrophotometer. A Tenor 27 spectrophotometer was used for scanning IR spectroscopy with KBr pellets. 1D and 2D NMR spectra were recorded on Bruker AM-400 and DRX-500 spectrometers with TMS as internal standard. Chemical shifts (δ) are expressed in parts per million with reference to the solvent signals. Mass spectra were performed on an API QSTAR time-of-flight spectrometer and a VG Autospec-3000 spectrometer, respectively. Semipreparative HPLC was performed on an Agilent 1100 liquid chromatograph with a Zorbax SB-C18 (9.4 mm×25 cm) column. Column chromatography was performed with silica gel (200–300 mesh, Qingdao Marine Chemical, Inc., Qingdao, People's Republic of China), and MCI gel (75–150 μ M, Mitsubishi Chemical Corporation, Tokyo, Japan). Fractions were monitored by TLC, and spots were visualized by heating silica gel plates sprayed with 10% H₂SO₄ in EtOH.

4.2. Collection and identification

The seeds of *K. ananosma* were collected in Simao Country of Yunnan Province, People's Republic of China, in October 2008, and identified by Prof. Xi-Wen Li, Kunming Institute of Botany. A voucher specimen (KIB 08102010) has been deposited in the Herbarium of the Kunming Institute of Botany, Chinese Academy of Sciences.

4.3. Extraction and isolation

The air-dried and powdered seeds of *K. ananosma* (250 g) were extracted with 70% aqueous Me₂CO (3×500 mL) at room temperature and concentrated in vacuo to yield a residue, which was partitioned between H₂O and EtOAc. The EtOAc extract (6.5 g) was chromatographed on MCI CHP 20P gel eluting with 90% CH₃OH–H₂O. The 90% CH₃OH–H₂O fraction (5.0 g) was subjected to silica gel (200–300 mesh) column chromatography, using a CHCl₃–Me₂CO gradient system (9:1, 8:2, 2:1, 1:1, 0:1) to yield 4 fractions. Semipreparative HPLC separation of the subfraction 1 (68% CH₃CN–H₂O, 3 mL min^{−1}) afforded compounds **2** (120 mg), **3** (8 mg), **4** (1.5 mg), **5** (3 mg), **6** (10 mg), **7** (69 mg), and **15** (64 mg). Semipreparative HPLC separation of the subfraction 2 (63% CH₃CN–H₂O, 3 mL min^{−1}) gave compounds **1** (2 mg), **8** (22 mg), **9** (4 mg), **10** (32 mg), **11** (5 mg), **12** (11 mg), and **14** (21 mg). Semipreparative HPLC separation of the subfraction 3 (60% CH₃CN–H₂O, 3 mL min^{−1}) produced compounds **13** (3 mg) and **19** (25 mg). Semipreparative HPLC separation of the subfraction 4 (50% CH₃CN–H₂O, 3 mL min^{−1}) yielded **16** (9 mg), **17** (12 mg), and **18** (3 mg).

4.3.1. Ananonin A (1). White solid; $[\alpha]_{\text{D}}^{27}$ −40.3 (c 0.24, CHCl₃); CD λ_{max} (CH₃OH)/nm ($\Delta\epsilon$) 225 (+25), 248 (−30); UV λ_{max} (CHCl₃)/nm (log ϵ) 241 (4.14), 221 (3.77), 214 (3.75); IR ν_{max} (KBr)/cm^{−1} 3444, 2924, 1733, 1268; ¹H and ¹³C NMR data (see Tables 1 and 3); (+)-ESIMS m/z 559 (100) $[M+Na]^+$; (+)-HRESIMS m/z 559.1930 $[M+Na]^+$ (calcd for C₃₀H₃₂O₉Na, 559.1944).

4.3.2. Ananonin B (2). white solid; $[\alpha]_{\text{D}}^{29}$ −48.8 (c 0.18, CHCl₃); CD λ_{max} (CH₃OH)/nm ($\Delta\epsilon$) 225 (+10), 247 (−11); UV λ_{max} (CHCl₃)/nm (log ϵ) 241 (4.15), 225 (3.58), 203 (3.70), 199 (3.71); IR ν_{max} (KBr)/cm^{−1}

Table 1¹H NMR data of **1–7** in CDCl₃, δ in ppm (J in Hz)

H	1 ^a	2 ^a	3 ^a	4 ^a	5 ^a	6 ^b	7 ^a
4	6.77 (s)	6.71 (s)	6.70 (s)	6.72 (s)	6.73 (s)	6.72 (s)	6.71 (s)
6	5.98 (d, 7.0)	6.01 (d, 7.1)	6.01 (d, 7.1)	6.02 (d, 7.1)	6.02 (d, 7.2)	6.02 (d, 7.3)	5.83 (d, 8.1)
7	2.27 (m)	2.28 (m)	2.27 (m)	2.29 (m)	2.29 (m)	2.29 (m)	2.17 (m)
8	2.27 (m)	2.37 (m)	2.36 (m)	2.38 (m)	2.39 (m)	2.39 (m)	2.22 (m)
9	4.71 (s)	5.75 (d, 1.7)	5.76 (d, 1.7)	5.80 (s)	5.78 (s)	5.79 (d, 2.2)	5.77 (br s)
11	6.39 (s)	6.51 (s)	6.52 (s)	6.53 (s)	6.54 (s)	6.54 (s)	6.45 (s)
17	1.01 (d, 6.9)	0.98 (d, 7.2)	0.97 (d, 7.2)	0.98 (d, 7.2)	1.00 (d, 7.2)	0.99 (d, 7.2)	1.02 (d, 8.0)
18	1.19 (d, 6.6)	1.10 (d, 7.1)	1.09 (d, 7.1)	1.09 (d, 6.7)	1.10 (d, 7.0)	1.10 (d, 7.1)	1.15 (d, 8.0)
3'	7.59 (m)	7.53 (m)	7.52 (d, 5.8)	7.55 (br s)	7.56 (m)	7.57 (m)	5.98 (overlap)
4'	7.32 (t, 7.7)	7.30 (t, 7.7)	7.30 (dd, 7.4, 5.8)	7.32 (t, 7.7)	7.32 (t, 7.7)	7.34 (t, 7.7)	1.87 (d, 7.2)
5'	7.51 (t, 7.4)	7.47 (t, 7.4)	7.47 (t, 7.4)	7.49 (t, 7.4)	7.49 (t, 7.3)	7.49 (t, 7.4)	1.54 (s)
6'	7.32 (t, 7.7)	7.30 (t, 7.7)	7.30 (dd, 7.4, 5.8)	7.32 (t, 7.7)	7.32 (t, 7.7)	7.34 (t, 7.7)	
7'	7.59 (m)	7.53 (m)	7.52 (d, 5.8)	7.55 (br s)	7.56 (m)	7.57 (m)	
2''			1.85 (m)	1.79 (m)	1.98 (m)	1.78 (m)	1.75 (m)
			1.79 (m)				
3''			0.86 (t, 7.6)	1.37 (m)	0.90 (d, 7.0)	1.38 (m)	1.38 (m)
						1.25 (m)	1.25 (m)
4''				0.80 (t, 7.4)	0.90 (d, 7.0)	0.76 (t, 7.4)	0.74 (t, 7.4)
5''						0.89 (d, 7.1)	0.87 (d, 6.9)
AcO-9		1.60 (s)					
MeO-1	3.65 (s)	3.58 (s)	3.57 (s)	3.59 (s)	3.62 (s)	3.65 (s)	3.62 (s)
MeO-2	3.54 (s)	3.47 (s)	3.46 (s)	3.48 (s)	3.49 (s)	3.49 (s)	3.90 (s)
MeO-3	3.92 (s)	3.95 (s)	3.90 (s)	3.92 (s)	3.92 (s)	3.94 (s)	3.93 (s)
MeO-14	3.88 (s)	3.85 (s)	3.84 (s)	3.84 (s)	3.85 (s)	3.85 (s)	3.77 (s)
OCH ₂ O	5.91 (s)	5.86 (s)	5.86 (s)	5.88 (s)	5.88 (s)	5.88 (s)	5.98 (s)
	5.85 (s)	5.83 (s)	5.83 (s)	5.86 (s)	5.86 (s)	5.86 (s)	5.94 (s)

^a Recorded at 500 MHz.^b Recorded at 400 MHz.**Table 2**¹³C NMR data of **1–7** in CDCl₃, δ in ppm

C	1 ^a	2 ^a	3 ^b	4 ^a	5 ^a	6 ^b	7 ^a
1	152.6 (s)	151.7 (s)	151.6 (s)	151.8 (s)	151.8 (s)	151.7 (s)	151.8 (s)
2	142.1 (s)	141.1 (s)	141.0 (s)	142.0 (s)	141.2 (s)	141.0 (s)	141.1 (s)
3	152.4 (s)	151.7 (s)	151.7 (s)	151.8 (s)	151.8 (s)	151.7 (s)	151.5 (s)
4	110.6 (d)	109.9 (d)	109.8 (d)	110.1 (d)	110.1 (d)	109.9 (d)	110.0 (d)
5	131.0 (s)	130.9 (s)	130.9 (s)	130.9 (s)	130.8 (s)	130.8 (s)	131.1 (s)
6	81.5 (d)	81.4 (d)	81.4 (d)	81.4 (d)	81.5 (d)	81.4 (d)	80.6 (d)
7	39.3 (d)	38.2 (d)	39.1 (d)	39.1 (d)	39.0 (d)	38.9 (d)	38.4 (d)
8	39.3 (d)	39.1 (d)	38.1 (d)	39.1 (d)	39.0 (d)	39.0 (d)	38.3 (d)
9	81.7 (d)	81.4 (d)	81.4 (d)	81.0 (d)	81.5 (d)	81.0 (d)	80.5 (d)
10	136.9 (s)	133.4 (s)	133.6 (s)	133.6 (s)	133.6 (s)	133.6 (s)	133.1 (s)
11	101.9 (d)	102.1 (d)	102.2 (d)	102.3 (d)	102.5 (d)	102.4 (d)	102.4 (d)
12	148.8 (s)	148.6 (s)	148.5 (s)	148.6 (s)	148.6 (s)	148.5 (s)	148.5 (s)
13	135.4 (s)	135.8 (s)	135.8 (s)	136.0 (s)	135.9 (s)	135.8 (s)	135.8 (s)
14	141.4 (s)	141.3 (s)	141.0 (s)	142.0 (s)	141.3 (s)	141.5 (s)	141.3 (s)
15	119.7 (s)	121.1 (s)	121.0 (s)	121.3 (s)	121.3 (s)	121.3 (s)	121.2 (s)
16	121.9 (s)	123.0 (s)	122.2 (s)	122.5 (s)	123.0 (s)	123.0 (s)	122.5 (s)
17	15.8 (q)	17.7 (q)	14.8 (q)	14.8 (q)	15.2 (q)	15.2 (q)	15.8 (q)
18	17.5 (q)	17.8 (q)	14.8 (q)	14.8 (q)	15.2 (q)	15.2 (q)	15.8 (q)
1'	165.4 (s)	165.3 (s)	165.3 (s)	165.3 (s)	165.3 (s)	165.3 (s)	166.7 (s)
2'	130.1 (s)	130.0 (s)	130.0 (s)	130.1 (s)	130.1 (s)	130.0 (s)	127.9 (s)
3'	129.6 (d)	129.5 (d)	129.5 (d)	129.6 (d)	129.6 (d)	129.5 (d)	138.5 (d)
4'	127.9 (d)	127.9 (d)	127.9 (d)	127.9 (d)	127.9 (d)	127.9 (d)	15.5 (q)
5'	132.8 (d)	132.8 (d)	132.8 (d)	132.7 (d)	132.7 (d)	132.7 (d)	19.9 (q)
6'	127.9 (d)	127.9 (d)	127.9 (d)	127.9 (d)	127.9 (d)	127.9 (d)	
7'	129.6 (d)	129.5 (d)	129.5 (d)	129.6 (d)	129.6 (d)	129.5 (d)	
1''			173.5 (s)	172.8 (s)	176.5 (s)	176.0 (s)	176.0 (s)
2''			27.1 (t)	35.8 (t)	33.7 (d)	40.2 (d)	40.1 (d)
3''			8.6 (q)	17.9 (t)	18.1 (q)	26.6 (t)	26.5 (t)
4''				13.6 (q)	19.3 (q)	11.2 (q)	11.1 (q)
5''						15.2 (q)	15.1 (q)
AcO-9		170.1 (s)					
		20.7 (q)					
MeO-1	60.6 (q)	60.3 (q)	60.4 (q)	60.4 (q)	60.6 (q)	60.4 (q)	60.4 (q)
MeO-2	59.1 (q)	59.0 (q)	60.4 (q)	59.0 (q)	59.0 (q)	60.6 (q)	60.4 (q)
MeO-3	56.0 (q)	56.0 (q)	55.9 (q)	56.0 (q)	56.0 (q)	55.9 (q)	55.8 (q)
MeO-14	60.8 (q)	60.5 (q)	59.0 (q)	60.5 (q)	60.4 (q)	58.9 (q)	59.2 (q)
OCH ₂ O	100.9 (t)	101.0 (t)	100.9 (t)	101.0 (t)	101.0 (t)	100.9 (t)	100.9 (t)

^a Recorded at 125 MHz.^b Recorded at 100 MHz.

Table 3¹H NMR data of **8–14** in CDCl₃, δ in ppm (500 MHz, *J* in Hz)

H	8^b	9^b	10^a	11^a	12^a	13^a	14^a
4	6.80 (s)	6.80 (s)	6.78 (s)	6.70 (s)	6.70 (s)	6.79 (s)	6.70 (s)
6	5.75 (d, 8.9)	5.75 (d, 7.2)	5.72 (d, 8.2)	5.75 (d, 8.8)	5.87 (d, 7.1)	6.08 (br s)	6.10 (br s)
7	2.11 (m)	2.13 (m)	2.08 (m)	2.05 (m)	2.07 (m)	2.27 (m)	2.24 (m)
8	2.24 (m)	2.27 (m)	2.23 (m)	2.11 (m)	2.18 (m)	2.27 (m)	2.34 (m)
9	5.72 (br s)	5.76 (d, 4.3)	5.75 (d, 3.6)	5.78 (d, 4.7)	5.72 (s)	4.73 (s)	5.78 (s)
11	6.38 (s)	6.40 (s)	6.48 (s)	6.58 (s)	6.56 (s)	6.59 (s)	6.68 (s)
17	0.96 (d, 7.1)	0.94 (d, 7.2)	0.94 (d, 7.1)	0.89 (d, 7.0)	0.88 (d, 7.0)	0.70 (d, 6.9)	0.83 (d, 7.0)
18	1.02 (d, 7.1)	1.03 (d, 7.1)	0.99 (d, 6.9)	0.96 (br s)	0.93 (br s)	0.99 (br s)	0.93 (br s)
3'	5.93 (overlap)	5.83 (overlap)	5.93 (overlap)		5.88 (overlap)	7.58 (m)	7.43 (overlap)
4'	1.84 (d, 7.2)	1.85 (dd, 7.2, 1.4)	1.82 (dd, 7.2, 1.4)		1.80 (d, 7.0)	7.29 (t, 7.6)	7.24 (t, 6.6)
5'	1.52 (s)	1.53 (s)	1.53 (s)		1.56 (s)	7.48 (t, 7.4)	7.42 (overlap)
6'						7.29 (t, 7.6)	7.24 (t, 6.6)
7'						7.58 (m)	7.43 (overlap)
2''		1.81 (m)	1.69 (m)				
3''		0.86 (t, 6.7)	1.34 (m), 1.19 (m)				
4''			0.72 (t, 7.4)				
5''			0.83 (d, 6.9)				
AcO-6				1.56 (s)			
AcO-9	1.56 (s)			1.56 (s)			1.58 (s)
MeO-1	3.55 (s)	3.55 (s)	3.56 (s)	3.60 (s)	3.53 (s)	3.66 (s)	3.58 (s)
MeO-2	3.89 (s)	3.90 (s)	3.86 (s)	3.87 (s)	3.83 (s)	3.88 (s)	3.82 (s)
MeO-3	3.92 (s)	3.93 (s)	3.89 (s)	3.89 (s)	3.87 (s)	3.93 (s)	3.89 (s)
MeO-13				4.01 (s)	3.86 (s)	3.93 (s)	3.89 (s)
MeO-14				3.65 (s)	3.48 (s)	3.34 (s)	3.64 (s)
OCH ₂ O	6.00 (s), 5.98 (s)	6.01 (s), 5.98 (s)	5.97 (s), 5.96 (s)				

^a Recorded at 500 MHz.^b Recorded at 400 MHz.

2937, 1740, 1716, 1106; ¹H and ¹³C NMR data (see [Tables 1 and 3](#)); (+)-ESIMS *m/z* 601 (100) [M+Na]⁺; (+)-HRESIMS *m/z* 601.2059 [M+Na]⁺ (calcd for C₃₂H₃₄O₁₀Na, 601.2049).

4.3.3. Ananonin C (3). White solid; [α]_D²⁸ −41.0 (c 0.16, CHCl₃); CD λ_{\max} (CH₃OH)/nm ($\Delta\epsilon$) 225 (+12), 247 (−10); UV λ_{\max} (CHCl₃)/nm (log ϵ) 241 (4.10), 219 (3.58), 199 (3.72); IR ν_{\max} (KBr)/cm^{−1} 2940, 1716, 1270; ¹H and ¹³C NMR data (see [Tables 1 and 3](#)); (+)-ESIMS *m/z* 615 (100) [M+Na]⁺; (+)-HRESIMS *m/z* 615.2190 [M+Na]⁺ (calcd for C₃₃H₃₆O₁₀Na, 615.2206).

4.3.4. Ananonin D (4). White solid; [α]_D²⁶ −18.1 (c 0.26, CHCl₃); CD λ_{\max} (CH₃OH)/nm ($\Delta\epsilon$) 225 (+5), 248 (−5); UV λ_{\max} (CHCl₃)/nm (log ϵ) 241 (3.95), 222 (3.57), 195 (3.56); IR ν_{\max} (KBr)/cm^{−1} 2964, 2935, 1734, 1720, 1270; ¹H and ¹³C NMR data (see [Tables 1 and 3](#)); (+)-ESIMS *m/z* 629 [M+Na]⁺; (+)-HRESIMS *m/z* 629.2366 [M+Na]⁺ (calcd for C₃₄H₃₈O₁₀Na, 629.2362).

4.3.5. Ananonin E (5). White solid; [α]_D²⁷ −21.7 (c 0.36, CHCl₃); CD λ_{\max} (CH₃OH)/nm ($\Delta\epsilon$) 225 (+20), 248 (−18); UV λ_{\max} (CHCl₃)/nm (log ϵ) 241 (3.95), 226 (3.58), 215 (3.55), 202 (3.55); IR ν_{\max} (KBr)/cm^{−1} 2925, 1733, 1716, 1270; ¹H and ¹³C NMR data (see [Tables 1 and 3](#)); (+)-FAB *m/z* 607 (100) [M+H]⁺; (+)-HRESIMS *m/z* 629.2367 [M+Na]⁺ (calcd for C₃₄H₃₈O₁₀Na, 629.2362).

4.3.6. Ananonin F (6). White solid; [α]_D²⁷ −5.5 (c 0.18, CHCl₃); CD λ_{\max} (CH₃OH)/nm ($\Delta\epsilon$) 225 (+15), 245 (−15); UV λ_{\max} (CHCl₃)/nm (log ϵ) 241 (4.10), 220 (3.75), 197 (3.72); IR ν_{\max} (KBr)/cm^{−1} 2967, 2936, 1722, 1107; ¹H and ¹³C NMR data (see [Tables 1 and 3](#)); (+)-ESIMS *m/z* 643 (12) [M+Na]⁺; (+)-HRESIMS *m/z* 643.2504 [M+Na]⁺ (calcd for C₃₅H₄₀O₁₀Na, 643.2519).

4.3.7. Ananonin G (7). White solid; [α]_D²⁹ +75.1 (c 0.19, CHCl₃); CD λ_{\max} (CH₃OH)/nm ($\Delta\epsilon$) 230 (+13), 250 (−5); UV λ_{\max} (CHCl₃)/nm (log ϵ) 241 (4.00), 231 (3.49), 223 (3.46), 200 (3.62); IR ν_{\max} (KBr)/cm^{−1} 2974, 2941, 1730, 1710, 1102; ¹H and ¹³C NMR data (see [Tables](#)

[1 and 3](#)); (+)-ESIMS *m/z* 621 (40) [M+Na]⁺; (+)-HRESIMS *m/z* 621.2660 [M+Na]⁺ (calcd for C₃₃H₄₂O₁₀Na, 621.2675).

4.3.8. Ananonin H (8). White solid; [α]_D²⁷ +49.3 (c 0.24, CHCl₃); CD λ_{\max} (CH₃OH)/nm ($\Delta\epsilon$) 225 (+20), 248 (−10); UV λ_{\max} (CHCl₃)/nm (log ϵ) 241 (4.10), 220 (3.78), 194 (3.78); IR ν_{\max} (KBr)/cm^{−1} 3435, 2968, 2938, 1738, 1715, 1235; ¹H and ¹³C NMR data (see [Tables 2 and 4](#)); (+)-ESIMS *m/z* 565 (30) [M+Na]⁺; (+)-HRESIMS *m/z* 565.2034 [M+Na]⁺ (calcd for C₂₉H₃₄O₁₀Na, 565.2049).

4.3.9. Ananonin I (9). White solid; [α]_D²⁸ +35.7 (c 0.18, CHCl₃); CD λ_{\max} (CH₃OH)/nm ($\Delta\epsilon$) 230 (+35), 248 (−18); UV λ_{\max} (CHCl₃)/nm (log ϵ) 241 (4.05), 200 (3.69), 198 (3.70); IR ν_{\max} (KBr)/cm^{−1} 3439, 2940, 1733, 1734, 1106; ¹H and ¹³C NMR data (see [Tables 2 and 4](#)); (+)-ESIMS *m/z* 579 (10) [M+Na]⁺; (+)-HRESIMS *m/z* 579.2212 [M+Na]⁺ (calcd for C₃₀H₃₆O₁₀Na, 579.2206).

4.3.10. Ananonin J (10). White solid; [α]_D²⁷ +69.9 (c 0.19, CHCl₃); CD λ_{\max} (CH₃OH)/nm ($\Delta\epsilon$) 230 (+25), 248 (−15); UV λ_{\max} (CHCl₃)/nm (log ϵ) 241 (4.06), 223 (3.71), 198 (3.70); IR ν_{\max} (KBr)/cm^{−1} 3434, 2936, 1733, 1729, 1714, 1106 cm^{−1}; ¹H and ¹³C NMR data (see [Tables 2 and 4](#)); (+)-ESIMS *m/z* 607 (100) [M+Na]⁺; (+)-HRESIMS *m/z* 607.2504 [M+Na]⁺ (calcd for C₃₂H₄₀O₁₀Na, 607.2519).

4.3.11. Ananonin K (11). White solid; [α]_D²⁷ +60.6 (c 0.19, CHCl₃); CD λ_{\max} (CH₃OH)/nm ($\Delta\epsilon$) 210 (+50), 250 (−25); UV λ_{\max} (CHCl₃)/nm (log ϵ) 241 (3.93), 221 (3.64), 215 (3.60); IR ν_{\max} (KBr)/cm^{−1} 3432, 2939, 1736, 1236; ¹H and ¹³C NMR data (see [Tables 2 and 4](#)); (+)-ESIMS *m/z* 541 (100) [M+Na]⁺; (+)-HRESIMS *m/z* 541.2059 [M+Na]⁺ (calcd for C₂₇H₃₄O₁₀Na, 541.2049).

4.3.12. Ananonin L (12). White solid; [α]_D²⁷ +58.3 (c 0.18, CHCl₃); CD λ_{\max} (CH₃OH)/nm ($\Delta\epsilon$) 210 (+19), 250 (−7); UV λ_{\max} (CHCl₃)/nm (log ϵ) 241 (3.92), 228 (3.62), 224 (3.62), 201 (3.58), 194 (3.59); IR ν_{\max} (KBr)/cm^{−1} 3429, 2939, 1741, 1712, 1231; ¹H and ¹³C NMR data

Table 4
¹³C NMR data of **8–14** in CDCl₃, δ in ppm

C	8 ^a	9 ^a	10 ^a	11 ^a	12 ^a	13 ^b	14 ^a
1	150.6 (s)	150.6 (s)	151.0 (s)	151.9 (s)	151.6 (s)	152.6 (s)	151.7 (s)
2	141.8 (s)	141.5 (s)	141.9 (s)	141.6 (s)	140.7 (s)	142.5 (s)	141.5 (s)
3	152.5 (s)	152.5 (s)	152.9 (s)	151.5 (s)	153.6 (s)	152.3 (s)	151.7 (s)
4	111.7 (d)	111.7 (d)	111.0 (d)	110.6 (d)	110.5 (d)	111.3 (d)	109.8 (d)
5	133.3 (s)	133.5 (s)	133.7 (s)	131.1 (s)	130.3 (s)	130.9 (s)	130.7 (s)
6	80.7 (d)	80.8 (d)	81.1 (d)	81.1 (d)	80.5 (d)	81.3 (d)	81.1 (d)
7	38.5 (d)	38.5 (d)	38.7 (d)	37.7 (d)	39.0 (d)	39.4 (d)	39.8 (d)
8	38.6 (d)	38.8 (d)	39.1 (d)	37.7 (d)	39.0 (d)	38.9 (d)	39.8 (d)
9	80.6 (d)	80.4 (d)	80.6 (d)	80.1 (d)	80.5 (d)	81.6 (d)	80.9 (d)
10	133.4 (s)	133.5 (s)	133.9 (s)	134.8 (s)	134.8 (s)	135.0 (s)	135.3 (s)
11	101.2 (d)	101.3 (d)	101.7 (d)	109.4 (d)	109.5 (d)	109.2 (d)	109.6 (d)
12	148.3 (s)	148.3 (s)	148.7 (s)	148.7 (s)	148.7 (s)	148.9 (s)	148.7 (s)
13	134.5 (s)	134.5 (s)	134.7 (s)	138.9 (s)	138.8 (s)	138.8 (s)	139.0 (s)
14	137.7 (s)	137.6 (s)	138.0 (s)	151.0 (s)	151.5 (s)	150.6 (s)	150.6 (s)
15	117.5 (s)	117.5 (s)	118.0 (s)	121.1 (s)	120.9 (s)	119.8 (s)	121.2 (s)
16	120.5 (s)	120.8 (s)	120.5 (s)	123.8 (s)	122.9 (s)	122.3 (s)	122.9 (s)
17	15.8 (q)	15.7 (q)	15.4 (q)	17.8 (q)	15.4 (q)	15.2 (q)	15.8 (q)
18	15.6 (q)	15.7 (q)	15.4 (q)	17.2 (q)	15.4 (q)	15.2 (q)	15.8 (q)
1'	166.7 (s)	166.8 (s)	167.1 (s)		166.7 (s)	165.4 (s)	165.3 (s)
2'	127.4 (s)	127.4 (s)	127.7 (s)		127.7 (s)	130.0 (s)	129.8 (s)
3'	139.0 (d)	139.1 (d)	139.3 (d)		138.8 (d)	129.6 (d)	129.5 (d)
4'	15.6 (q)	15.7 (q)	16.0 (q)		15.6 (q)	128.1 (d)	128.1 (d)
5'	20.0 (q)	20.0 (q)	20.4 (q)		20.7 (q)	132.9 (d)	133.0 (d)
6'						128.1 (d)	128.1 (d)
7'						129.6 (d)	129.5 (d)
1''		173.4 (s)	176.2 (s)				
2''		27.1 (t)	40.5 (d)				
3''		8.6 (q)	26.8 (t)				
4''			11.4 (q)				
5''			15.3 (q)				
AcO-6				170.0 (s), 21.0 (q)			
AcO-9	169.9 (s) 20.6 (q)			170.0 (s), 20.6 (q)	170.0 (s), 20.7 (q)		170.0 (s), 20.7 (q)
MeO-1	60.8 (q)	60.8 (q)	61.1 (q)	60.2 (q)	60.1 (q)	60.3 (q)	60.3 (q)
MeO-2	60.7 (q)	60.8 (q)	61.2 (q)	60.5 (q)	60.6 (q)	60.6 (q)	60.4 (q)
MeO-3	56.1 (q)	56.1 (q)	56.3 (q)	56.0 (q)	55.9 (q)	56.0 (q)	56.0 (q)
MeO-13				60.8 (q)	60.6 (q)	60.9 (q)	60.6 (q)
MeO-14				59.9 (q)	59.9 (q)	59.7 (q)	59.5 (q)
OCH ₂ O	101.7 (t)	101.7 (t)	102.0 (t)				

^a Recorded at 100 MHz.^b Recorded at 125 MHz.**Table 5**
Neuroprotective effects of compounds **1–3** and **4–19** on SH-SY5Y cells

Compound	H ₂ O ₂ (100 μM)		Vehicle	Compound	H ₂ O ₂ (100 μM)		Vehicle
	Test concentration (μM)				Test concentration (μM)		
	1	10			1	10	
1	58.0±1.4	59.2±1.0	58.6±1.9	11	65.3±1.5	66.7±0.5	60.3±1.1
2	48.4±2.2	49.52±2.0	52.9±3.8	12	56.7±1.5 ^a	53.5±0.8	51.34±1.2
3	61.5±1.3	65.8±0.2 ^b	60.31±1.1	13	68.4±2.0 ^b	66.2±1.4 ^a	59.4±0.7
5	60.5±1.5	55.6±0.6	58.6±1.9	14	59.3±1.1 ^a	55.2±1.1 ^b	64.8±1.9
6	53.4±1.2	56.1±3.9	53.7±1.6	15	53.6±1.0	45.7±1.1 ^a	50.9±1.0
7	58.2±2.9 ^a	68.2±2.8	65.4±3.0	16	68.7±2.0	65.0±2.3 ^b	73.0±1.6
8	61.3±3.6	64.8±3.8	63.14±1.7	17	62.7±1.3	64.0±1.1	64.8±1.9
9	67.3±1.3 ^a	69.0±2.1	73.0±1.6	18	56.5±1.6 ^a	53.7±1.0	51.3±1.2
10	61.0±1.2	55.9±1.1	60.31±1.1	19	61.3±1.0	65.1±2.1	66.6±0.8

^a *p*<0.05 versus H₂O₂ group.^b *p*<0.01 versus H₂O₂ group.

(see Tables 2 and 4); (+)-ESIMS *m/z* 581 (10) [M+Na]⁺; (+)-HRESIMS *m/z* 581.2352 [M+Na]⁺ (calcd for C₃₀H₃₈O₁₀Na, 581.2362).

4.3.13. Ananonin M (13). White solid; [α]_D²⁶ −50.3 (c 0.22, CHCl₃); CD λ_{max} (CH₃OH)/nm (Δε) 225 (+23), 240 (−30); UV λ_{max} (CHCl₃)/nm (log ε) 241 (4.13), 230 (3.70), 224 (3.69), 204 (3.74); IR ν_{max} (KBr)/cm^{−1} 3424, 2932, 1714, 1597, 1270; ¹H and ¹³C NMR data (see

Tables 2 and 4); (+)-ESIMS *m/z* 561 (80) [M+Na]⁺; (+)-HRESIMS *m/z* 561.2092 [M+Na]⁺ (calcd for C₃₀H₃₄O₉Na, 561.2100).

4.3.14. Ananonin N (14). White solid; [α]_D²⁸ −52.1 (c 0.18, CHCl₃); CD λ_{max} (CH₃OH)/nm (Δε) 220 (+7), 240 (−6); UV λ_{max} (CHCl₃)/nm (log ε) 241 (4.08), 219 (3.62), 198 (3.72); IR ν_{max} (KBr)/cm^{−1} 3432, 2939, 1740, 1716, 1257; ¹H and ¹³C NMR data (see Tables 2 and 4);

(+)-ESIMS m/z 603 (100) $[M+Na]^+$; (+)-HRESIMS m/z 603.2207 $[M+Na]^+$ (calcd for $C_{32}H_{36}O_{10}Na$, 603.2208).

4.4. Cell survival assay

SH-SY5Y neuroblastoma cells were obtained from ATCC (American Type Culture Collection) and maintained at 37 °C in a humidified atmosphere containing 5% CO_2 . Cells were seeded into 96-well plates (Greiner) at a density of 5×10^4 cells per mL in DMEM/F12 (Gibco), supplemented with 10% heat-inactivated bovine calf serum, 100 units/mL penicillin, and 100 mg/mL streptomycin. All experiments were carried out 24 h after cells were seeded. Appropriate concentrations of hydrogen peroxide (H_2O_2) were prepared in deionized water on the day of application to cultures. The SH-SY5Y cells were preincubated with different compounds 2 h before H_2O_2 (1 mM) was added, and the assay for cell viability was performed 24 h after H_2O_2 was added. Cell survival was evaluated by reduction of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma).²⁵ The values of cell survival were normalized against the values for control group, which was set to 100%. Data were evaluated for statistical significance with one-way ANOVA followed by LSD test by using a computerized statistical package. Differences were considered significant at $p < 0.05$.

Acknowledgements

This work was supported financially by the NSFC (No. 30830115 to H.-D.S., and 20902093 to J.-X.P.), the Science and Technology Program of Yunnan Province (2008GA031), the Major State Basic Research Development Program of China (Nos. 2009CB522300 and 200940900), the Western Doctoral Foundation of Chinese Academy of Sciences (J.-X.P.), the CAS action-plan for West Development (KZCX2-XB2-15), and the National Science & Technology Major Project 'Key New Drug Creation and Manufacturing Program of China' (No. 2009ZX09301-001 and 063).

Supplementary data

Supplementary data associated with this article can be found in the online version, at [doi:10.1016/j.tet.2011.04.105](https://doi.org/10.1016/j.tet.2011.04.105). These data

include MOL files and InChIKeys of the most important compounds described in this article.

References and notes

- Wang, W.; Liu, J. Z.; Liu, R. X.; Xu, Z. R.; Yang, M.; Wang, W. X.; Liu, P.; Sabia, G.; Wang, X. M.; Guo, D. A. *Planta Med.* **2006**, *72*, 284–288.
- Wang, W.; Xu, Z.; Yang, M.; Liu, R.; Wang, W.; Liu, P.; Guo, D. A. *Magn. Reson. Chem.* **2007**, *45*, 522–526.
- Chen, M.; Jia, Z. W.; Chen, D. F. *J. Asian Nat. Prod. Res.* **2006**, *8*, 643–648.
- Kuo, Y. H.; Wu, M. D.; Huang, R. L.; Kuo, L. M.; Hsu, Y. W.; Liaw, C. C.; Hung, C. C.; Shen, Y. C.; Ong, C. W. *Planta Med.* **2005**, *71*, 646–653.
- Chen, D. F.; Zhang, S. X.; Kozuka, M.; Sun, Q. Z.; Feng, J.; Wang, Q.; Mukainaka, T.; Nobukuni, Y.; Tokuda, H.; Nishino, H.; Wang, H. K.; Morris-Natschke, S. L.; Lee, K. H. *J. Nat. Prod.* **2002**, *65*, 1242–1245.
- Chen, D. F.; Zhang, S. X.; Chen, K.; Zhou, B. N.; Wang, P.; Cosentino, L. M.; Lee, K. H. *J. Nat. Prod.* **1996**, *59*, 1066–1068.
- Chen, D. F.; Zhang, S. X.; Xie, L.; Xie, J. X.; Chen, K.; Kashiwada, Y.; Zhou, B. N.; Wang, P.; Cosentino, L. M.; Lee, K. H. *Bioorg. Med. Chem.* **1997**, *5*, 1715–1723.
- Kuo, Y. H.; Huang, H. C.; Kuo, L. M. Y.; Chen, C. F. *J. Org. Chem.* **1999**, *64*, 7023–7027.
- Liu, Y. H. *Flora of China*; Science: Shanghai, 1996; Vol. 30; 234.
- Chen, Y. G.; Hai, L. N.; Liao, X. R.; Qin, G. W.; Xie, Y. Y.; Halaweish, F. J. *J. Nat. Prod.* **2004**, *67*, 875–877.
- Chen, Y. G.; Xie, Y. Y.; Cheng, K. F.; Cheung, K. K.; Qin, G. W. *Phytochemistry* **2001**, *58*, 1277–1280.
- Chen, Y. G.; Song, X. P.; Hai, L. N.; Fang, A.; Bi, Y. M.; Liao, X. R. *Pol. J. Chem.* **2006**, *80*, 1677–1681.
- Chen, Y. G.; Song, X. P.; Hai, L. N.; Lv, Y. P.; Fang, A.; Halaweish, F.; Liao, X. R. *Pharmazie* **2006**, *61*, 891–892.
- Zou, C.; Pu, X. Y.; Zhou, J. *Acta Bot. Yunnan* **1993**, *15*, 196–200.
- Yang, J. H.; Pu, J. X.; Wen, J.; Li, X. N.; He, F.; Xue, Y. B.; Wang, Y. Y.; Li, Y.; Xiao, W. L.; Sun, H. D. *J. Nat. Prod.* **2010**, *73*, 12–16.
- Yang, J. H.; Wen, J.; Du, X.; Li, X. N.; Wang, Y. Y.; Li, Y.; Xiao, W. L.; Pu, J. X.; Sun, H. D. *Tetrahedron* **2010**, *66*, 8880–8887.
- Li, X. N.; Pu, J. X.; Du, X.; Yang, L. M.; An, H. M.; Lei, C.; He, F.; Luo, X.; Zheng, Y. T.; Lu, Y.; Xiao, W. L.; Sun, H. D. *J. Nat. Prod.* **2009**, *72*, 1133–1141.
- Li, Z. Y.; Li, L. *Zhongcaoyao* **1996**, *27*, 3–4.
- Gao, X. M.; Pu, J. X.; Huang, S. X.; Yang, L. M.; Huang, H.; Xiao, W. L.; Zheng, Y. T.; Sun, H. D. *J. Nat. Prod.* **2008**, *71*, 558–563.
- Zhang, H. J.; Tan, G. T.; Santarsiero, B. D.; Mesecar, A. D.; Hung, N. V.; Cuong, N. M.; Soejarto, D. D.; Pezzuto, J. M.; Fong, H. H. S. *J. Nat. Prod.* **2003**, *66*, 609–615.
- Ikeya, Y.; Taguchi, H.; Yosioka, I.; Kobayashi, H. *Chem. Pharm. Bull.* **1979**, *27*, 1383–1394.
- Xiao, X. Q.; Yang, J. W.; Tang, X. C. *Neurosci. Lett.* **1999**, *275*, 73–76.
- Chetsawang, B.; Putthaprasart, C.; Phansuwan-Pujito, P.; Govitrapong, P. *J. Pineal Res.* **2006**, *41*, 116–123.
- Zhang, M.; Shoeb, M.; Goswamy, L. J. P.; Xiao, T. L.; Hogan, D.; Campbell, G. A.; Ansari, N. H. *J. Neurosci. Res.* **2010**, *88*, 686–694.
- Hansen, M. B.; Nielsen, S. E.; Berg, K. J. *Immunol. Methods* **1989**, *119*, 203–210.